Simcere seeking appro for generic zanamavir
Simcere Pharmaceutical, a Chinese manufacturer and supplier of branded, generic and innovative cancer drugs, is seeking approval to manufacture and sell products containing zanamivir, one of only two World Health Organization-approved drugs to which the new H1N1 strain of influenza A has been shown to be susceptible.
UK drug major GlaxoSmithKline granted a zanamivir license to Simcere in 2006 and the firm is the only pharmaceutical company in mainland China that has such a license.
"We look forward to obtaining the approval to manufacture and sell zanamivir in China. To this end, we have already begun to prepare the raw materials and manufacturing facilities required to launch this drug," said Xiaojin Yin, Simcere's senior vice president of R&D.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze